A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells

Cancer Immunology, Immunotherapy

Volumn 57, Issue 1, 2008, Pages 43-52

  Buhler P ^a   Wolf, P ^a   Gierschner, D ^a   Schaber, I ^a   Katzenwadel, A ^a   Schultze Seemann, W ^a   Wetterauer, U ^a   Tacke, M ^a   Swamy, M ^a   Schamel, W W A ^a   Elsasser Beile U ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Immunotherapy; Prostate cancer; PSMAxCD3 bispecific diabody; T cell targeting

Indexed keywords

CD3 ANTIGEN; CD3 ANTIGEN ANTIBODY; METAL; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOTHERAPY; IN VIVO STUDY; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN PURIFICATION; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; BLOTTING, WESTERN; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; JURKAT CELLS; MALE; MICE; MICE, SCID; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35748956820     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0348-6     Document Type: Article

References (34)

1. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H (1993) Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82:1803-1812
2. Bolhuis RL, Hoogenboom HR, Gratama JW (1996) Targeting of peripheral blood T lymphocytes. Springer Semin Immunopathol 18:211-226
3. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AM, Goey SH, Gratama JW, Lamers CH, et al. (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463-1469
4. Chambers CA, Allison JP (1999) Costimulatory regulation of T-cell function. Curr Opin Cell Biol 11:203-210
5. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192-3198
6. Cochlovius B, Kipriyanov SM, Stassar MJ, Christ O, Schuhmacher J, Strauss G, Moldenhauer G, Little M (2000) Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells. J Immunol 165:888-895
7. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, Kufer P, Lutterbuse R, Riethmuller G, Gjorstrup P, Bargou RC (2003) T-cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B-cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 170:4397-4402
8. Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66:1359-1370
9. Gao Y, Xiong D, Yang M, Liu H, Peng H, Shao X, Xu Y, Xu C, Fan D, Qin L, Yang C, Zhu Z (2004) Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Leukemia 18:513-520
10. Ghosh A, Heston WD (2004) Tumor target prostate-specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539
11. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL (1998) Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 58:4787-4789
12. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136
13. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8-29
14. Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA, Little M (1997) Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 10:445-453
15. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 293:41-56
16. Kipriyanov SM, Moldenhauer G, Strauss G, Little M (1998) Bispecific CD3 × CD19 diabody for T-cell mediated lysis of malignant human B cells. Int J Cancer 77:763-772
17. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629-3634
18. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098-2103
19. MacDonald GC, Glover N (2005) Effective tumor targeting: strategies for the delivery of armed antibodies. Curr Opin Drug Discov Devel 8:177-183
20. Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH (1998) Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate- specific membrane antigen. J Urol 160:2396-2401
21. Perisic O, Webb PA, Holliger P, Winter G, Williams RL (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217-1226
22. Schagger H, Cramer WA, von Jagow G (1994) Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. Anal Biochem 217:220-230
23. Schamel WW, Reth M (2000) Monomeric and oligomeric complexes of the B cell antigen receptor. Immunity 13:5-14
24. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA (2005) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65:2882-2889
25. Schlereth B, Kleindienst P, Fichtner I, Lorenczewski G, Brischwein K, Lippold S, da Silva A, Locher M, Kischel R, Lutterbuse R, Kufer P, Baeuerle PA (2006) Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother 55:785-796
26. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA (2006) T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 55:503-514
27. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028
28. Swamy M, Kulathu Y, Ernst S, Reth M, Schamel WW (2006) Two-dimensional Blue Native-/SDS-PAGE analysis of SLP family adaptor protein complexes. Immunol Lett 104:131-137
29. Swamy M, Siegers GM, Minguet S, Wollscheid B, Schamel WW (2006) Blue native polyacrylamide gel electrophoresis (BN-PAGE) for the identification and analysis of multiprotein complexes. Sci STKE 345:l4
30. Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL (2001) Identification of prostate-specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. Int J Cancer 92:871-876
31. Weiner GJ, Degast GC (1995) Bispecific monoclonal antibody therapy of B-cell malignancy. Leuk Lymphoma 16:199-207
32. Wolf H, Freimann U, Jung G (1994) Target cell induced T-cell activation with bispecific antibodies: a new concept for tumor immunotherapy. Recent Results Cancer Res 135:185-195
33. Wolf P, Gierschner D, Buhler P, Wetterauer U, Elsasser-Beile U (2006) A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol Immunother 55:1367-1373
34. Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R, Hu SZ, Odom-Maryon T, Wong JY, Shively JE (1996) Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2:21-36